Sinovac Biotech (SVA) 20-F2010 FY Annual report (foreign)

Filed: 22 Apr 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Good

New words: absolved, Accretion, Acctrue, affluent, agreeable, arrive, arrived, Baruch, BiliveTM, Biochemistry, budget, CanSino, Chaminade, child, circumstance, cohort, cold, comparison, composing, conclusion, copyright, creativity, DD, deceased, deletion, Deliotte, Deloitte, deprecation, depth, destruction, disaggregated, Dr, dynamic, England, entrance, EPI, falling, fierce, fiercer, forma, formal, fragment, hemisphere, HNTE, Ho, Honolulu, inflation, inhibiting, instruction, Jacob, Jaffray, lawsuit, leader, lent, lieu, logistic, Macao, Madrid, Maryland, media, MedImmune, mice, Ming, MOA, Nepal, NIBSC, NIFDC, Northern, Oxford, parcel, payoff, penumococcal, Pfizer, pharmacopoeia, Philippine, Piper, polysaccharide, Port, POV, PPV, premise, QA, QC, qualification, ratio, ready, recall, reexamine, remitted, roadmap, run, SAE, septicemia, Shanxi, shelve, SinoBioway, software, static, stemmed, Sydney, tender, Texaco, thande, Tianjin, Tianjing, Tohmatsu, Topic, totrace, Touche, troubled, UBS, unfounded, unsold, VICH, waiting, win, Xia, Zone

Removed: Academy, accrual, AG, annum, ARB, assistant, automated, Berna, Bethune, blood, buy, Canadian, canceled, Capitalization, Changjun, comfort, cooperation, default, deputy, EMBA, fake, FAS, floating, Fu, Guangxin, Holland, inactive, instrument, Jiansan, Jinling, Kangtai, Lab, Machinery, measure, measuring, NICPBP, Norman, oversaw, parent, penalty, practical, preclinical, Premier, processed, Prophylactic, Qin, regular, reliably, rendering, routinely, Session, Shukang, simplify, stabilize, stayed, subscribe, Sun, sustain, trace, Wen

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 13.2

Certification by the Chief Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Sinovac Biotech Ltd. (the “Company”) on Form 20-F for the year ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jacob Chik Keung Ho, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 22, 2011

By:	/s/ Jacob Chik Keung Ho
	Name: Jacob Chik Keung Ho
	Title: Chief Financial Officer